Business Update4 Nov 2026, 05:10 pm
Bliss GVS Pharma Subsidiary Gets MHRA Approval for Mesalazine
AI Summary
Bliss GVS Pharma Limited announced that its wholly owned subsidiary, Asterisk Lifesciences Ltd, UK, has received marketing authorization from the Medicines & Healthcare products Regulatory Agency (MHRA) for Mesalazine 1g Suppositories. This approval signifies a significant step for the subsidiary's product line and market presence in the UK.
Key Highlights
- Subsidiary Asterisk Lifesciences Ltd, UK, secured MHRA marketing authorization.
- Product approved is Mesalazine 1g Suppositories.
- This is a key regulatory milestone for the subsidiary.
- Enhances product portfolio and market access in the UK.
Price Impact
More from BLISSGVS